

## Original data/Peer-Reviewed Publications

1. Reipold EI, Easterbrook P, Trianni A, Panneer N, Krakower, Ongarello S, Roberts T, **Miller V**, Denkinger C. Optimising diagnosis of viremic hepatitis C infection: the development of a target product profile. *BMC Infectious Diseases*. 2017. DOI 10.1186/s12879-017-2770-5
2. Tucker JD, Meyers K, Best J, Kaplan K, Pendse R, Fenton KA, Andrieux-Meyer I, Figueroa C, Goicochea P, Gore C, Ishizaki A, Khwairakpam G, **Miller V**, Mozalevskis A, Ninburg M, Ocama P, Peeling R, Walsh N, Colombo MG, Easterbrook P. The HepTestContest: a global innovation contest to identify approaches to hepatitis B and C testing. *BMC Infectious Diseases* 2017 DOI 10.1186/s12879-017-2771-4
3. Siddiqui MS, Harrison SA, Abdelmalek MF, Anstee QM, Bedossa P, Castera L, Dimick-Santos L, Friedman S, Greene K, Kleiner D, Megnien S, Neuschwander-Tetri BA, Ratziu V, Schabel E, **Miller V**, Sanyal AJ, On behalf of the Liver Forum Case Definitions Working Group. Case definitions for inclusion and analysis of endpoints in clinical trials for NASH through the lens of regulatory science. *Hepatology*. 2017. DOI: 10.1002/hep.29607
4. Dube K, Dee L, Evans D, Sylla L, Taylor J, Brown B, **Miller V**, Corneli A, Skinner A, Greene SB, Tucker JD, Rennie S. Perceptions of equipoise, risk/benefit ratios, and “otherwise healthy volunteers” in the context of early-phase HIV cure research in the United States – A qualitative inquiry. *J Empirical Research on Human Research Ethics*. 2017. In press.
5. Patel YA, Imperial JC, Muir A, Quentin M, Debrot DJ, Dimick-Santos L, Filozof C, Metha R, Sanyal AS, Schabel E, Neuschwander-Tetri BA, **Miller V**. Baseline parameters in clinical trials for nonalcoholic steatohepatitis: Recommendations from the Liver Forum. *Gastroenterology* 2017; in press. doi: 10.1053/j.gastro.2017.07.024.
6. Bartlett SR, Grebely J, Eltahla AA, Reeves JD, Howe AYM, **Miller V**, Ceccherini-Silberstein F, Bull RA, Douglas MW, Dore GJ, Harrington P, Lloyd AR, Jacka B, Mathews GV, Wang GP, Pawlotsky J-M, Feld JJ, Schinkel J, Garcia F, Lennerstrand J, Applegate TL. Sequencing of hepatitis C virus for detection of resistance to direct-acting antiviral therapy: A systematic review. *Hepatology Communications* 2017; in press. doi: 10.1002/hep4.1050
7. Natori Y, Algahamdi A, Tazari Mahmood, **Miller V**, Husain S, Komatsu T, Griffiths P, Ljungman P, Orchanian-Cheff A, Kumar D, Humar A. Can Viral Load be used as a Surrogate Marker in Clinical Studies of Cytomegalovirus in Solid Organ Transplantation: A Systematic Review and Meta-analysis. *CMV. CID* 2017. In press. doi: 10.1093/cid/cix793
8. Liu, J, Goicochea P, Block T, Brosgart CL, Donaldson EF, Lenz O, Lim SG, Marins EG, Mishra P, Peters MG, **Miller V**. Advancing the regulatory path on hepatitis B virus treatment and curative research: A stakeholders’ consultation.

Journal of Virus Eradication 2017; 3:1-6

9. Ljungman P, Boeckh M, Hirsch HH, Josephson F, Lundgren J, Nichols G, Pikis A, Razonable RR, **Miller V**, Griffiths PD. Definitions of CMV infection and disease in transplant patients for use in clinical trials. CID 2017; 64(1):87-91. doi: 10.1093/cid/ciw668
10. McIntosh M, Hauschild B, **Miller V**. Human cytomegalovirus and transplantation: drug development and regulatory issues. Journal of Virus Eradication 2016; 2:143-248
11. Sanyal AJ, **Miller V**. Regulatory science and drug approval for alcoholic and non-alcoholic steatohepatitis. Gastroenterology 2016; 150 (8) 1723-27. doi: 10.1053/j.gastro.2016.02.044. Epub 2016 Feb 26.
12. Lontok E, Harrington P, Howe A, Kieffer T, Lennerstrand J, Lenz O, McPhee F, Mo H, Parkin N, Pilot-Matias T, **Miller V**. Hepatitis C Virus drug resistance-associated substitutions: State of the art summary. Hepatology 2015; 62:1623-32. doi: 10.1002/hep.27934. Epub 2015 Jul 30
13. **Miller V**, Grant RM. Regulatory considerations for antiretroviral prophylaxis to prevent HIV acquisition. Clin Pharmacology & Therapeutics 2014; 96(2): 162-5. doi: 10.1038/clpt.2014.114
14. Hutchison C, Kwong A, Ray S, Struble K, Swan T, **Miller V**. Accelerating drug development through collaboration: The hepatitis C drug development advisory group (HCV DrAG). Clin Pharmacology & Therapeutics 2014; 96(2):153-55. doi: 10.1038/clpt.2014.113
15. Panneer N, Lontok E, Branson BM, Teo C-G, Dan C, Parker M, Stekler JD, DeMaria A, **Miller V**. HIV and HCV Testing: HIV and hepatitis C virus infection in the United States: Whom and how to test. Clin Infect Dis. 2014; 59(6): 875-882. doi: 10.1093/cid/ciu396
16. Lontok E, Mani N, Harrington PR, **Miller V**. Closing in on the target: sustained virologic response in hepatitis C virus genotype 1 infection response-guided therapy. Clin Infect Dis. 2013; 56(10):1466-70. doi: 10.1093/cid/cit025
17. Houssaini A, Assoumou L, **Miller V**, Calvez V, Marcelin AG, Flandre P. Scoring methods for building genotypic scores: an application to didanosine resistance in a large derivation set. PLoS One 2013; 8(3): e59014. doi:10.1371/journal.pone.0059014
18. **Miller V**, Nwokike J, Stergachis A. Pharmacovigilance and global HIV/AIDS. Curr Opin HIV AIDS 2012; 7:299-304. doi: 10.1097/COH.0b013e328354d8e7
19. Wedemeyer H, Jensen DM, Dogofsky E, Mani N, Pawlotsky JM, **Miller V**. Recommendations for standardized nomenclature and definitions of viral response in trials of HCV investigational agents. Hepatology 2012; 56:2398-2403. doi:

10.1002/hep.25888

20. Mani N, Murray J, Gulick RM, Josephson F, **Miller V**, Miele P, Strobos J, Struble K. Novel clinical trial designs for the development of new antiretroviral agents. AIDS 2012;26:899-907. doi: 10.1097/QAD.0b013e3283519371
21. Triant VA, Josephson F, Rochester CG, Althoff KN, Marcus K, Munk R, Cooper C, D'Agostino RB, Costagliola D, Sabin CA, Williams PL, Hughes S, Post WS, Chandra-Strobos N, Guaraldi G, Young SS, Obenchain R, Bedimo R, **Miller V**, Strobos J. Adverse outcome analysis of observational data: Assessing cardiovascular risk in HIV disease. CID 2012;54:408- 13. doi: 10.1093/cid/cir829
22. Hauschild B, Weddle A, Lubinski C, Tegelvik JK, **Miller V**, Saag M. HIV clinic capacity and medical workforce challenges: Results of a survey of Ryan White Part C-funded programs. Annals of the Forum for Collaborative HIV Research 2011; 13
23. Bakare N, Edwards IR, Stergachis A, Pal S, Holmes CB, Lindquist M, Duncombe C, Doodoo A, Novendstern J, Nwokike J, Kuchenbecker R, Aberg JA, **Miller V**, Strobos J. Global pharmacovigilance for antiretroviral drugs: Overcoming contrasting priorities. PLOS Med 2011; 8(7): e1001054. doi: 10.1371/journal.pmed.1001054
24. Kwong A, Najera I, Bechtel J, Bowden S, Fitzgibbon J, Harrington P, Kempf D, Kieffer TL, Koletzki D, Kukolj G, Lim S, Pilot-Matias T, Lin K, Mani N, Mo H, O'Rear J, Otto M, Parkin N, Pawlotsky J-M, Petropoulos C, Picchio G, Raltston R, Reeves JD, Schooley RT, Seiwert S, Standring D, Stuyver L, Sullivan J, **Miller V**. Sequence and phenotypic analysis for resistance monitoring in hepatitis C virus drug development: Recommendations from the HCV DRAG. Gastroenterology 2011; 140:755-760, doi: 10.1053/j.gastro.2011.01.029
25. DeGruttola V, Smith DM, Little SJ, **Miller V**. Developing and evaluating comprehensive HIV control strategies: Issues and Challenges. CID 2010;50 (Suppl 3) S102-S107. doi: 10.1086/651480
26. Assoumou L, Houssaini A, Costagliola D, Flandre P on behalf of the **Standardization and Clinical Relevance of HIV Drug Resistance Testing Project** of the Forum for Collaborative HIV Research. Relative contributions of baseline patient characteristics and the choice of statistical methods to the variability of genotypic resistance scores: the example of didanosine. Journal of Antimicrob Chemother 2010;65:752-760. doi:10.1093/jac/dkq034
27. Assoumou L, Cozzi-Lepri A, Brun-Vezinet F, DeGruttola V, Kuritzkes D, Phillips A, Zolopa A, **Miller V**, Flandre P, Costagliola D on behalf of the Standardization and Clinical Relevance of HIV Drug Resistance Testing project of the Forum for Collaborative HIV Research. Initiatives for developing and comparing genotype interpretation systems: development of a didanosine genotypic resistance interpretation system based on large derivation and validation datasets. AIDS 2010; 24:365-371.

28. **Miller V.** The Forum for Collaborative HIV Research – a model for an integrated and inclusive approach to clinical research and drug development. Clinical Pharmacology & Therapeutics 2009; 86:332-335. doi: 10.1038/clpt.2009.140
29. Cheng B, Landay A, **Miller V.** Research needs and challenges in the development of HIV diagnostic and treatment monitoring tests for use in resource-limited settings. Current Opinion in HIV AIDS 2008; 3:495-503. doi: 10.1097/COH.0b013e328303e5f9
30. Chan-Tack KM, Struble KA, Morgensztejn N, Murray JS, Gulick R, Cheng B, Weller I, **Miller V.** HIV clinical trial design for antiretroviral development: moving forward. AIDS 2008; 30:2419-2427. doi: 10.1097/QAD.0b013e32831692e6
31. Bartlett JG, Branson BM, Fenton K, Hauschild BC, **Miller V,** Mayer K. Opt-out testing for HIV: A progress report. JAMA 2008; 300:945-951
32. Assoumou L, Brun-Vezinet F, Cozz-Lepri A, Kuritzkes D, Phillips A, Zolopa A, DeGruttola V, **Miller, V,** Costagliola D, on behalf of the Standardization and Clinical Relevance of HIV Drug Resistance Testing Working Group. Initiatives for developing and comparing genotype interpretation systems: external validation of existing systems for didanosine against virological response. J Inf Dis 2008; 198:470-480. doi: 10.1086/590156
33. Cozzi-Lepri A on behalf of the Standardization and Clinical Relevance of HIV Drug Resistance Testing Working Group. Initiatives for developing and comparing genotype interpretation systems: external validation of existing rule-based interpretation systems for abacavir against virological response. HIV Med 2008; 9:27-40. doi: 10.1111/j.1468-1293.2008.00523.x.
34. Lederman MM, **Miller V,** Weller I, Deeks S. A new approach for "deep" salvage trials in advanced HIV infection. AIDS 2007; 21:1503-1506. doi:10.1097/QAD.0b013e3281338384
35. **Miller V.** Buprenorphine and HIV primary care: Report of a Forum for Collaborative HIV Research Workshop. CID 2006; 43:S253-S257. doi:10.1086/508190
36. Shafer RW, Rhee S-Y, Pillay D, **Miller V,** Sandstrom P, Schapiro J, Kuritzkes DR, Bennett D. HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance. AIDS 2007; 21:215-223. doi:10.1097/QAD.0b013e328011e691
37. Fiscus SA, Cheng B, Crowe SM, Demeter L, Jennings C, **Miller V,** Respass R, Stevens W. HIV-1 viral load assays for resource-limited settings. PLOS Medicine 2006; 3:e417. doi: 10.1371/journal.pmed.0030417
38. Bickel M, Rickerts V, Stephan C, Jacobi V, Rottmann C, Dauer B, Carlebach A, Thalhammer A, **Miller V,** Staszewski S. The Protease Inhibitor Transfer Study (PROTRA1): abacavir and efavirenz in combination as a substitute for a protease inhibitor in heavily pretreated HIV-1 infected patients with undetectable plasma viral

- load. HIV Medicine 2005;6: 179-184. doi: 10.1111/j.1468-1293.2005.00286.x
39. Struble K, Murray J, Cheng B, Gegeny T, **Miller V**, Gulick R. Antiretroviral therapies for treatment-experienced patients: current status and research challenges. AIDS 2005;19:747-756.
40. Vandamme AM, Sonnerborg A, Ait-Khaled M, Albert J, Asjo B, Bachelier L, Banhegyi D, Boucher C, Brun-Vezinet F, Camacho R, Clevenbergh P, Clumeck N, Dedes N, De Luca a, Doerr HW, Faudon JL, Gaddi G, Gerstoft J, Hall WW, Hatzakis A, Hellmann N, Horban A, Lundgren JD, Kempf D, Miller M, **Miller V**, Myers TW, Nielsen C, Opravil M, Palmisano L, Perno DF, Phillips A, Pillay D, Pumarola T, Ruiz L, Salminen M, Schapiro J, Schmidt B, Schmit JC, Schuurman R, Shulse E, Soriano V, Staszewski S, Vella S, Youle M, Ziermann R, Perrin L. Updated European recommendations for the clinical use of HIV drug resistance testing. Antiviral Therapy 2004; 9:829-848.
41. Brun-Vezinet F, Costagliola D, Ait Khaled M, Calvez V, Clavel F, Clotet B, Haubrich R, Kempf D, King M, Kuritzkes D, Lanier R, Miller M, **Miller V**, Phillips A, Pillay D, Schapiro J, Scott J, Shafer R, Zazzi M, Zolopa A, DeGruttola V. Clinically validated genotype analysis: guiding principles and statistical concerns. Antiviral Therapy 2004; 9:465-478.
42. Bisson G, Gross R, Evans S, Graham D, Lundgren J, Murray J, Arlett P, Pizzuti D, Primohamed M, Kerft-Jais C, Szarfman A, Justice A, Munk B, Carr A, **Miller V**, Weller I, Walker A. Monitoring of long-term toxicities of HIV treatments: an international perspective. AIDS 2003; 17:2407-2417. doi:10.1097/01.aids.0000096891.73209.9c
43. Boffito M, Back DJ, Blaschke TF, Rowland M, Bertz RJ, Gerber JG, **Miller V** on behalf of the Roundtable Participants. Roundtable Discussion Report: Protein binding in antiretroviral therapies. AIDS Research and Human Retroviruses 2003; 19:825-835. doi:10.1089/088922203769232629
44. Reddy YS, Kashuba A, Gerber J, **Miller V**. Roundtable Report: Importance of antiretroviral drug concentrations in sanctuary sites and viral reservoirs. AIDS Research and Human Retroviruses 2003; 19:167-176. doi:10.1089/088922203763315669
45. Cozzi-Lepri A, Phillips AN, **Miller V**, Katlama C, Ledergerber B, Vella S, Weber J, Bruun JN, Kirk O, Clotet B, Lundgren JD. Changes in viral load in people with virological failure who remain on the same HAART regimen. Antiviral Therapy 2003; 8:127-136.
46. Greub G, Cozzi-Lepri A, Ledergerber B, Staszewski S, Perrin L, **Miller V**, et al. Intermittent and sustained low-level HIV viral rebound in patients receiving potent antiretroviral therapy. AIDS 2002; 16:1967-1968.
47. **Miller V**, Stark T, Loelliger AE, Lange JMA. The impact of the M184V substitution in HIV reverse transcriptase on treatment response. HIV Medicine 2002; 3:135-145. doi: 10.1046/j.1468-1293.2002.00101.x
48. **Miller V**, Mocroft A, Clotet B, Ledergerber B, Kirk O, D'Arminio Monforte A, Lundgren J

- for the EuroSIDA Study Group. Association of viral load, CD4 cell count and treatment with clinical progression in HIV patients with very low CD4 cell counts: The EuroSIDA study. J Infect. Dis. 2002; 186:189-97. doi:10.1086/341466
49. **Miller V**, Larder B. Mutational patterns in the HIV genome and cross resistance following nucleoside and nucleotide analogue drug exposure. Antiviral Therapy 2001; 6 (Suppl 3): 25-44.
50. Phillips AN, Staszewski S, Weber R, Kirk O, Francioli P, **Miller V**, Vernazza P, Lundgren J, Ledergerber B, on behalf of the Swiss HIV Cohort Study, the Frankfurt HIV Clinic Cohort, and the EuroSIDA Study Group. Initiation of antiretroviral therapy: HIV-1 viral load response according to the baseline CD4 lymphocyte count and viral load. JAMA 2001; 286:2560-2567. doi:10.1001/jama.286.20.2560
51. Kirk O, Pedersen C, Cozzi-Lepri A, Antunes F, **Miller V**, Gatell JM, Katlama C, Lazzarin A, Skinhf P, Barton SE, for the EuroSIDA study Group. Non-Hodgkin lymphoma in HIV- infected patients in the era of highly active antiviral therapy. Blood 2001; 98:3406-3412. doi:10.1182/blood.V98.12.3406
52. Phillips A, **Miller V**, Sabin C, Cozzi Lepri A, Klauke S, Bickel M, Doerr HW, Hill A, Staszewski S. Durability of viral suppression after initial decline in HIV-1 viral load to <50 copies/ml with highly active antiretroviral therapy. AIDS 2001; 15:2379-2384.
53. Harrigan PR, Montaner JSG, Wegner SA, Verbiest W, **Miller V**, Wood R, Larder BA. World- wide variation in HIV-1 phenotypic susceptibility in untreated individuals: biologically relevant values for resistance testing. AIDS 2001; 15 (13):1671-1677.
54. Kirk O, Mocroft A, Pradier C, Bruun JN, Hemmer R, Clotet B, **Miller V**, Viard J-P, Phillips AN, Lundgren JD, and the EuroSIDA Study Group. Clinical outcome among HIV- infected patients starting saquinavir hard gel compared to ritonavir or indinavir. AIDS 2001; 15(8):999- 1008.
55. Vandamme A-M, Houyez F, Bânhegyi D, Clotet B, De Schrijver G, De Smet KAL, Hall WW, Harrigan R, Hellmann N, Hertogs K, Holtzer C, Larder B, Pillay D, Race E, Schmit JC, Schuurman R, Shulse E, Sønnerborg A, **Miller V**. Laboratory guidelines for the practical use of HIV drug resistance tests in patient follow-up. Antiviral Therapy 2001; 6:21-40.
56. Mocroft A, Phillips AN, **Miller V**, Gatell J, van Lunzen J, Parkin JM, Francioli P, Roegge B, Lazzarin A, Lindgren JD on behalf of the EuroSIDA Study Group. The use of and response to second-line protease inhibitor (PI) regimens: Results from the EuroSIDA Study. AIDS 2001 Jan 26; 15(2):201-209.
57. **Miller V**. Resistance to HIV-1 Protease Inhibitors. J Acquir Immune Defic Syndr. 2001 Mar 1; 26 Suppl 1:S34-50.

58. **Miller V**. Structured Treatment Interruptions (STI) in Antiretroviral Management of HIV-1. Current Opinion in Infectious Diseases 2001; 14:29-37.
59. Cozzi Lepri A, **Miller V**, Phillips AN, Rabenau H, Sabin CA, Staszewski S. The virological response to HAART over the first 24 weeks of therapy according to the pre-therapy viralload and the week 4-8 viral load. AIDS 2001; (15):47-54.
60. EuroGuidelines Group: Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing in treatment management: Recommendations for the European setting. AIDS 2001; 15 (3):309-320.
61. Gröschel B, **Miller V**, Doerr HW, Cinatl Jr. C. Activity of cellular thymidine kinase 1 in PBMCs of HIV-1 infected patients: novel therapy marker. Infection 2000; 28:209- 213. doi:10.1007/s150100070037
62. Staszewski S, Haberl A, Carlebach A, Rottmann C, **Miller V**, Gute P. A simple, once-daily dosing regimen for treating HIV-1 infection in intravenous drug users. HIV Medicine 2000; 1:162-163. doi: 10.1046/j.1468-1293.2000.00020.x
63. Youle M, Holtzer C, Simpson K, de Clerq K, **Miller V**. HIV-1 drug resistance testing: health outcomes issues. Antiviral Therapy 2000; 5:113-115.
64. Mocroft A, **Miller V**, Chiesi A, Blaxhult A, Katlama C, Clotet B, Barton S, Lundgren JD. Virological failure among patients on HAART from across Europe: Results from the EuroSIDA study. Antiviral Therapy 2000; 5: 107-112.
65. **Miller V**, Sabin C, Hertogs K, Larder B, Bloor S, Martinez-Picado J, D'Aquila R, Larder B, Lutz T, Gute P, Weidmann E, Rabenau H, Phillips A, Staszewski S. Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure. AIDS 2000; 14 (18): 2857-2867. doi: 10.1097/00002030-200012220- 00007
66. **Miller V**, Sabin C, Phillips AN, Rottmann C, Rabenau H., Weidmann E, Rickerts V, Findhammer S, Helm EB, Staszewski S. The impact of PI-containing HAART on progression of HIV disease and its relationship to CD4 and viral load. AIDS 2000; 14: 2129-2136.
67. DeGrutolla V, Dix L, D'Aquila R, Holder D, Phillips A, Ait-Kahled M, Baxter J, Clevenbergh P, Hammer S, Harrigan R, Katzenstein D, Lanier R, Miller M, Para M, Yerly S, Zolopa A, Jeffrey M, Patick A, **Miller V**, Pedneault L, Mellors J. The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antiviral Therapy 2000; 5:41-48.

68. **Miller V**, Cozzi-Lepri A, Hertogs K, Gute P, Larder B, Bloor S, Klauke S, Rabenau H, Phillips AN and Staszewski S. HIV drug susceptibility and treatment response to mega- HAART regimen in patients from the Frankfurt HIV Cohort. Antiviral Ther. 2000; 5:49-55.
69. Hertogs K, Bloor S, Kemp S, Van den Eynde C, Alcorn TM, Pauwels R, Van Houtte M, Staszewski S, **Miller V**, Larder BA. Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance. A survey of over 6000 samples. AIDS 2000; 14:1203-10.
70. Rizzardì GP, De Boer RJ, Hoover S, Tambussi G, Bart P-A, Chapuis A, Halkic N, Corpataux J- M, **Miller V**, Staszewski S, Notermans DW, Perrin L, Fox CH, Lange JMA, Lazzarin A, and Pantaleo G. Estimates of length of treatment required to suppress plasma viremia below 50 copies/ml in HIV-1-infected adults. J Clin Invest 2000;105(6):777-782.
71. Cozzi Lepri A, Sabin C, Staszewski S, Hertogs K, Müller A, Rabenau H, Phillips AN, **Miller V**. Resistance profiles in patients with viral rebound on potent antiretroviral therapy. J Infect Dis. 2000; 181:1143-1147. doi: 10.1086/315301
72. Hertogs K, Bloor S, De Vroey V, Van den Eynde C, Dehertog P, Cauwenberge AV, Stürmer M, Alcorn T, Wegner S, Van Houtte M, **Miller V**, Larder BA. A novel human immunodeficiency virus type 1 (HIV-1) reverse transcriptase mutational pattern confers phenotypic 3TC resistance in the absence of mutation 184V. Antimicrob. Agents Chemother. 2000; 44(3):568-573.
73. Holtkamp N, Otteken A, Findhammer S, **Miller V**, Kurth R, Werner A. Unexpected co- receptor usage of primary HIV-1 isolates from viremic patients under highly active antiretroviral therapy (HAART). J Infect Dis 2000; 181:513-521. doi: 10.1086/315240
74. **Miller V**, Ait-Khaled A, Stone C, Griffin P, Mesogiti D, Cutrell A, Harrigan R, Staszewski S, Katlama C, Pearce G and Tisdale M. HIV-1 reverse transcriptase (RT) genotype and viral sensitivity to RT inhibitors during abacavir monotherapy and after switch to zidovudine, lamivudine and abacavir HAART. AIDS 2000 Jan 28; 14 (2):163-171.
75. Chiesi A, Mocroft A, Dally LG, **Miller V**, Katlama C, Ledergerber B, Pedersen C, Phillips AN, Arcieri R, and Lundgren JD, for the EuroSIDA Study Group. Regional survival differences across Europe in HIV positive people: The EuroSIDA Study. AIDS 1999; 13:2281-2288.
76. Larder BA, Bloor S, Kemp SD, Hertogs K, Desmet RL, **Miller V**, Stürmer M, Staszewski S, Ren J, Stammers DK, Stuart DI, Pauwels R. A family of insertion mutations between codons 67 and 70 of human immunodeficiency virus type 1 reverse transcriptase confer multi- nucleoside analog resistance. Antimicrob.



Agents Chemother. 1999; 43 (8):1961-7.

77. Hertogs K, Van Houtte M, Larder B, **Miller V**. Testing for HIV-1 drug resistance: New developments and clinical implications. Recent Res. Devel. Antimicrob. Agent & Chemother. 1999; 3:83-104.
78. **Miller V**, Staszewski S, Sabin C, Carlebach A, Rottmann C, Weidmann E, Rabenau H, Hill A, Cozzi Lepri A, Phillips AN. CD4 lymphocyte count as a predictor of the duration of HAART- induced suppression of HIV-1 virus load. J Infect Dis. 1999; 180:530-533. doi:10.1086/314890
79. **Miller V**, Staszewski S, Nisius G, Cozzi Lepri A, Sabin C, Phillips AN. Risk of new AIDS diseases in patients on triple therapy. Research letter, Lancet, 1999; 353:463. dx.doi:10.1016/S0140-6736(98)04954-X
80. **Miller V**, Mocroft A, Reiss P, Katlama C, Papadopoulos AI, Katzenstein T, van Lunzen J, Antunes F, Phillips AN, Lundgren J. Relations among CD4 count nadir, antiretroviral therapy and HIV-1 disease progression: results from the EuroSIDA study. Annals of Internal Medicine, 1999; 130:570-577. doi: 10.7326/0003-4819-130-7-199904060-00005
81. Staszewski S, **Miller V**, Sabin C, Schlecht C, Gute P, Stamm S, Leder T, Berger A, Weidmann E, Hill A, Phillips A. Determinants of sustainable CD4 lymphocyte count increases in response to antiretroviral therapy. AIDS 1999; 13:951-956.  
dx.doi.org/10.1097/00002030-199905280-00011
82. Staszewski S, **Miller V**, Sabin C, Carlebach A, Berger Anna-Marie, Weidmann E, Helm EB, Hill A, Phillips A. Virological response to protease inhibitor therapy in an HIV clinical cohort. AIDS 1999; 13:367-373.
83. Staszewski S, **Miller V**, Sabin C, Berger A, Hill AM, Phillips AN. Rebound of HIV-1 viral load after suppression to very low level [Research Letter] AIDS 1998; 12:2360.
84. **Miller V**, de Béthune M-P, Kober A, Stürmer M, Hertogs K, Pauwels R, Stoffels P, Staszewski S. Patterns of resistance and cross-resistance to HIV-1 reverse transcriptase inhibitors in patients treated with the non-nucleoside reverse transcriptase inhibitor loviride. Antimicrob. Agents Chemother. 1998; 42:3123-3129.
85. Mocroft A, Vella S, Benfield T, Chiesi A, **Miller V**, Kosmidins J, d'Arminio Monteforte, Yust I, Bruun J, Phillips AN, Lundgren JD for the EUROSDIA study group. Changing patterns of mortality in patients infected with HIV. Lancet 1998; 352:1725-1730.
86. **Miller V**, Stürmer M, Staszewski S, Gröschel B, Hertogs K, de Béthune M-P, Pauwels R, Harrigan PR, Bloor S, Kemp SD, Larder BA. The M184V mutation in HIV-1 reverse

transcriptase conferring 3TC resistance does not result in broad cross-resistance tonucleoside analogue RT inhibitors. AIDS 1998; 12:705-712.

87. Hertogs K, de Béthune MP, **Miller V**, Ivens T, Schel P, Van Cauwenberge A, Van den Eynde C, Van Gerwen V, Azijn H, Van Houtte M, Peeters F, Staszewski S, Conant M, Bloor S, Kemp S, Larder B, Pauwels R. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant HIV-1 isolates of patients treated with antiretroviral drugs. Antimicrob. Agents Chemoth. 1998, 42:269-276.
88. **Miller V**, Phillips A, Rottmann C, Staszewski S, Pauwels R, Hertogs K, de Béthune M- P, Kemp SD, Bloor S, Harrigan PR, Larder BA. Dual resistance to zidovudine /ZDV) and lamivudine (3TC) in patients treated with ZDV/3TC combination therapy: Association with therapy failure. Journal of Infect. Dis. 1998; 177:1521-32.
89. Muller P, Engelstadter M, Werner A, Braner J, Staszewski S, **Miller V**, Doerr HW, Kurth R, Cichutek K. Increased serum and mRNA levels of RANTES associated with elevated levels of activated CD8+CD38+ T cells in HIV-1 infected individuals. Intervirology 1997; 40:263- 270.
90. Staszewski S, Phillips A, Nisius G, **Miller V**. Virological, immunological and clinical effects of stavudine-containing triple-combination therapies in pretreated HIV-1 positive patients. Antiviral Therapy, 1997; Volume 2 Supplement 3: Stavudine in the Management of HIV Infection, 133-135.
91. **Miller V**, Staszewski S, Boucher CAB, Phair JP. Clinical Experience with Nonnucleoside Reverse Transcriptase Inhibitors. AIDS 1997; 11(suppl A):S157-S164.
92. Staszewski S, Loveday C, Picazo JJ, Dellarnonica P, Skinhoj P, Johnson MA, Danner SA, Harrigan PR, Hill AM, Verity L, McDade H. for **the Lamivudine European HIV Working Group**. Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients. A randomized controlled comparison with zidovudine monotherapy. JAMA 1996; Jul 10; 276(2): 111-7.  
doi:10.1001/jama.1996.03540020033026
93. Staszewski S, **Miller V**, Rehm S. et. Al. Virological and immunological analysis of a triple combination pilot study with zidovudine, lamivudine and zidovudine in HIV-1-infected patients. AIDS 1996; 10:1-7. doi: 10.1097/00002030-199605000-00001

94. Staszewski S, **Miller V**, Kober A, et. Al. Evaluation of the efficacy and tolerance of R 018893, R 089439 (loviride) and placebo in asymptomatic HIV-1-infected patients. Antiviral Therapy 1996;1:42-50.
95. Davis LE, Hjelle BL, **Miller VE**, Palmer DL, Lewellyn AL, Merlin TL, Young SA, Mills RG, Wachsman W, Wiley CA. Early viral brain invasion of iatrogenic human immunodeficiency virus infection. Neurology, 1992.  
dx.doi:10.1212/WNL.42.9.1736
96. Willman CL, Stewart C, **Miller VE**, Tomasi TB. Regulation of MHC Class II gene expression in macrophages by hematopoietic colony stimulating factors: Induction by GM-CSF and inhibition by CSF-1. J Exp Med 1989; 170:1559.
97. **Miller VE**, Chow DA, Greenberg AH. Natural Antibodies. In: Nelson DS, ed. Natural Immunity. Academic Press, 1989.
98. **Miller VE**, Scofield VL. Role of sperm in HIV transmission. Proceedings from the CONRAD International Workshop: The Heterosexual Transmission of AIDS Norfolk VA, 1989. Alexander NJ, Gabelnick HL, Spieler JM, ed. Wiley-Liss, 1989.
99. **Miller VE**, Lagarde AE, Longenecker BM, Greenberg AH. A phenyl- $\beta$ -galactoside specific monoclonal antibody reactive with murine and rat NK cells. J Immunol 1986; 136:2968
100. Pohajdak B, Lee KC, Sugawara I, **Miller VE**, Wright JA, Greenberg AH. Comparative analysis of NK cell and macrophage recognition of ConA resistant Chinese Hamster Ovary Cells: The role of membrane oligosaccharides. JNCI 1986; 136:2968 doi: 10.1093/jnci/76.2.257
101. Greenberg AH, **Miller VE**, Jablonski T, Pohajdak B. Suppression of NK mediated natural resistance by interferon treatment of murine lymphomas. J. Immunol 1984;32:2129- 2134.
102. **Miller VE**, Pohajdak B, Greenberg AH, Murine natural anti-tumor antibody. III. Interferon treatment of a natural killer-resistant lymphoma: Augmentation of natural antibody reactivity and susceptibility to in vivo natural resistance. JNCI 1983;71:377-384.
103. Greenberg AH, **Miller VE**, Pohajdak B, Jablonski T. The in vivo effects of interferon suppression of the NK target structure. In: Herberman RB, ed. NK Cells and Other Natural Effector Cells. Academic Press, New York, 1982.

104. Chow DA, Carlson GA, **Miller VE**, Pohajdak B, Greenberg AH. Natural resistanceto tumors is a heterogeneous immunological phenomenon: Evidence for non-NK cell mechanisms. Invasion and Metastases 1982;1:205-219.